Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Maitreya Medicare's enterprise value is ₹1,556.1 Mil.
Maitreya Medicare's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 was ₹45.7 Mil. Therefore, Maitreya Medicare's EV-to-EBITDA for today is 34.09.
The historical rank and industry rank for Maitreya Medicare's EV-to-EBITDA or its related term are showing as below:
NSE:MAITREYA's EV-to-EBITDA is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 10.63 * Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Maitreya Medicare's PE Ratio (TTM) for today is calculated as:
Maitreya Medicare's share price for today is ₹112.25.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Maitreya Medicare's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was ₹3.749.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Maitreya Medicare's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Maitreya Medicare EV-to-EBITDA Chart
Maitreya Medicare Annual Data
Trend
Mar21
Mar22
Mar23
EV-to-EBITDA
0.00
0.00
0.00
Maitreya Medicare Semi-Annual Data
Mar21
Mar22
Mar23
Sep23
EV-to-EBITDA
0.00
0.00
0.00
0.00
NSE:MAITREYA vs HCA, DVA, THC: EV-to-EBITDA Comparison
For the Medical Care Facilities subindustry, Maitreya Medicare's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Maitreya Medicare EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Maitreya Medicare's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Maitreya Medicare's EV-to-EBITDA falls into.
Maitreya Medicare's current Enterprise Value is ₹1,556.1 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Maitreya Medicare's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 was ₹45.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Maitreya Medicare (NSE:MAITREYA) has a EV-to-EBITDA of 34.09 as of Aug. 26, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Maitreya Medicare.
Is Maitreya Medicare's EV-to-EBITDA too high?
Maitreya Medicare's current EV-to-EBITDA is 34.09. The Healthcare Providers & Services industry median EV-to-EBITDA is 10.63. Maitreya Medicare's value of 34.09 is 220.7% above this industry median. Overall, Maitreya Medicare has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Maitreya Medicare's EV-to-EBITDA compare to HCA and DVA?
Maitreya Medicare's EV-to-EBITDA of 34.09 can be compared against companies in the Healthcare Providers & Services industry. The industry median EV-to-EBITDA is 10.63. Maitreya Medicare's value of 34.09 is 220.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 10.63, based on 517 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Maitreya Medicare's current EV-to-EBITDA of 34.09 is 220.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Maitreya Medicare. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 10.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Maitreya Medicare's current EV-to-EBITDA is 34.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Maitreya Medicare stock overvalued right now?
Maitreya Medicare (NSE:MAITREYA) has a current EV-to-EBITDA of 34.09. The current EV-to-EBITDA is 34.09 and 220.7% above the Healthcare Providers & Services industry median of 10.63. Maitreya Medicare's overall GF Score™ is 18/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Maitreya Medicare (NSE:MAITREYA), the current EV-to-EBITDA is 34.09 as of Aug. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Maitreya Medicare Ltd is Multi Superspeciality hospital. It is a 125 bedded hospital that provides multi-disciplinary integrated healthcare services, with a focus on primary secondary & tertiary care, and also offers a comprehensive range of healthcare services across over 18 specialties and super specialties, including Cardiology, Urology, Oncology, Laparoscopic Surgery, Neurology, Neurosurgery, Spine Surgery, Nephrology including Dialysis, Gastroenterology, Gastrointestinal surgery, Cardiothoracic Surgery, Oncosurgery, Orthopedic Surgery including joint replacements and Arthroscopic surgeries, Gynecology & High-Risk Obstetrics, Hepatocellular Billary Surgery, Critical Care Medicine etc.
18GF Score
Get the complete analysis for NSE:MAITREYA
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:MAITREYA has been successfully added to your 
